X0306 4 2017-11-13 0 0001367644 Emergent BioSolutions Inc. EBS 0001380185 El-Hibri Fuad 400 PROFESSIONAL DRIVE, SUITE 400 GAITHERSBURG MD 20879 1 1 1 0 Chairman Common Stock 2017-11-13 4 S 0 20000 40.69 D 1510216 D Common Stock 2017-11-14 4 S 0 20000 40.05 D 1490216 D Common Stock 4344250 I By Intervac, L.L.C. Common Stock 1524155 I By Biovac, L.L.C. All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on February 28, 2017 that is intended to comply with Rule 10b5-1(c) under the Exchange Act. The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.26 to $40.98. The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.81 to $40.55. Mr. El-Hibri's wife, individually, and Mr. and Mrs. El-Hibri, as tenants by the entirety, collectively hold an aggregate 40.65% equity interest in Intervac, L.L.C., which in turn is the direct owner of 4,344,250 shares of the Issuer's common stock. Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Intervac, L.L.C. for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein. Mr. El-Hibri, individually, and Mr. and Mrs. El-Hibri, as tenants by the entirety, collectively hold an aggregate 89.2% equity interest in Biovac, L.L.C, which in turn is the direct owner of 1,524,155 shares of the Issuer's common stock. Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Biovac, L.L.C. for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein. /s/ Carl A. Valenstein, attorney-in-fact 2017-11-15